Genocea Biosciences Inc. buy Quitte
Summary
This prediction ended on 22.05.19 with a price of €4.12. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.84%. Quitte has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | -4,93 % | -11,98 % | -3,49 % | 44,54 % |
| iShares Nasdaq 100 | -2,63 % | -2,22 % | 13,78 % | 80,99 % |
| iShares Nikkei 225® | -4,73 % | -10,90 % | 19,71 % | 45,26 % |
| iShares S&P 500 | -2,54 % | -3,54 % | 8,88 % | 61,12 % |
Comments by Quitte for this prediction
In the thread Genocea Biosciences Inc. diskutieren
geh wieder rein
Quitte stimmt am 08.04.2019 dem Buy-Gesamtsentiment mit dem Kursziel 1.0$ zu.
Stopped prediction by Quitte for Genocea Biosciences Inc.
Genocea Biosciences Inc.
05.01.21
05.01.22
06.01.22
Genocea Biosciences Inc.
05.06.18
05.12.18
05.12.18